Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
It's getting picked up by local news in the area, won't be long before national media get in touch with the patient to ask him about the treatment.
https://www.thetelegraphandargus.co.uk/news/18602487.bradford-researchers-forefront-major-covid-19-treatment-trial/
Dr Dinesh Saralaya, who has led the trial, said:
“We were pleased that Bradford was chosen for the Synairgen treatment trial and this came about as a result of close links with fellow researchers at the University of Southampton, which was instrumental in the development of the drug, SNG001.
“The trial involved patients inhaling the drug directly into their lungs using a nebuliser, and the results have been very successful.
“So far we have recruited six patients to the study; five of whom responded very well and improved quickly. The patients were all in the early stages of Covid-19 and were at risk of developing severe disease which could require ventilation.
And the link...
https://www.bradfordhospitals.nhs.uk/2020/07/23/bradford-teaching-hospitals-at-the-forefront-of-major-covid-19-treatment-trial/
Mr Imishue, aged 55, is a Mental Health Care Support Worker with Bradford District Care NHS Foundation Trust.
On April 18, 2020, he was admitted to Bradford Royal Infirmary with coronavirus (Covid-19.) He was prescribed the drug SNG001 via nebuliser to stop his symptoms worsening and prevent the need for being placed on ventilation.
Mr Imishue said: “I was very breathless and had a persistent cough. I also felt very lethargic. When I tested positive for Covid-19, I was asked by Dr Saralya if I was willing to take part in the treatment trial and I said yes.
“The treatment had a profound positive effect on me and my symptoms improved so that I was able to go home, where I continued with the treatment. The staff kept regular checks on me, asking how I was getting along and I was able to report that I was feeling much better. I took the treatment for 14 days.
“I am happy to say that I have now been able to return to work. I feel very fortunate I was able to take part in the trial.”
This is excellent news, really positive interview. To be honest I don't want Synairgen to be bought out, i'd rather them work with a big pharma to scale up distribution and keep hold of profits. The long term gains from COPD treatment will far outweigh covid treatment and it's better for my pension pot to keep hold of this long-term growth rather than loose it in a quick buyout.
Saying that, i'm almost certain a buyout will come. The situation in America is worsening and local outbreaks are cropping up all over Europe. The question is who will buy, the government here are desperate for good news and will fight to protect SNG from foreign control. The Americans are desperate for a successful treatment and have the clout to buy out at many multiples of the current price.
As Richard said, things will move very fast and if that RNS drops with a takeover figure there's no chance of getting back in.
Wow, well there you go folks. I warned people about the panorama ramp, largegin dismisses me, called me a bore and fraud. All the while he agreed with my warning, but chose to belittle and insult me so he could make more money. Make your minds up who to believe next time
@largegin you’ve called me a bore and a fraud and I’m the abusive one? Do you understand why I take personal exception to you. As far as I’m aware I’ve not personally insulted you, I have just asked you to apologise and recognise when you have been proved wrong. Was I a fraud for warning people not to believe the hype before Panorama?
And another one for you @notnow20 , have a read and then either tell me they are also wrong or you’re wrong.
https://www.researchgate.net/publication/228319833_The_Impact_of_Manipulation_in_Internet_Stock_Message_Boards
@notnow20 There are many reports into share price manipulation by pumpers and hypers, I’m surprised you’ve not heard of this before. A simple Google’s search before you post next time
https://onlinelibrary.wiley.com/doi/10.1111/j.1468-5957.2011.02258.x
@largegin you’re right, I was blaming people for predicting £1+ after Panorama and hyping the programme by saying people wouldn’t be able to buy in the next day. It was obvious people were hyping to cash out after the programme. This sort of trading ruins the credibility of a share. I think you were one of the people who told me to shut up and for people to ignore me. Unfortunately everything I said came true, and you disappeared the next day. There is no need to sulk about it, perhaps just recognise when you’re wrong and apologise?
Ahead of this week and potential announcements by the company I thought a bit of gentle speculation might be in order.
There’s been a significant number of research reports released over the weekend that point to interferon beta as the treatment with the best chance of success against Covid-19.
All studies to date involving interferon beta in Covid 19 patients and in cell models have ALL resulted in success.
To me the SNG study is no longer 50/50, it’s just a question of how successful the results will be. I’m expecting the home trial results to be the real game changer, but I suspect positive results from the hospital trials to catapult the share. The anticipation of positive home trial results will be priced into the rise after the hospital trial in my opinion.
Do people think an indication of a positive home trial result might come earlier than we think. Perhaps on the RNS we are expecting soon on home trial procedure. This would certainly help recruitment for the home trials, particularly with the urgency required in the care home situation.
Check out the press coverage of the recent Honk Kong study showing interferon beta working. New York Times among others who are hailing interferon beta as our best hope for treatment. This is going to snowball over the next few days as more and more people pick up on interferon beta treatment. There will be a huge amount of attention on the Synairgen results, this is the study that people are waiting for.
"Triple antiviral therapy with #interferon beta-1b, #lopinavir–ritonavir, and #ribavirin were safe and superior to lopinavir–ritonavir alone in shortening virus shedding, alleviating symptoms, and facilitating discharge of patients with mild to moderate #COVID19."
Another stinking find. I’m so pleased this board has moved on from silly ramping and predicting share prices. We’ve now got intelligent posts with interesting research findings. I’ll take some time to read this, but a quick skim read sounds like this supports the SnG001 treatment.
Again I feel we are just ahead of the curve with research, the media, governments and scientist will be digesting this over the weekend. Get ready for the day when people start talking about interferons in everyday conversation
https://www.medrxiv.org/content/10.1101/2020.04.19.20068015v1.full.pdf
This is another report highlighting impaired interferon levels in patients with severe covid19 symptoms. The past week or so there has been a substantial number of publications highlighting impaired interferon levels as one of the primary underlying reasons why this disease is so ‘effective’
It won’t be long before ‘interferon’ becomes a household name. People will then start to look to companies who are working in this field.
Just my musings, but we’ve been so concentrated on promoting Synairgen. All we need to do is wait for the media/government and public to pick up on this growing body of research and they will seek us out. These research reports are days old, only those who are working on the field or invested will be reading them, it’s going to take a few days to trickle through, but it will, you only have to look at recent Twitter chatter between scientists talking about interferon treatment as a potential solution. At that point the attention turns away from the vaccine, to interferons and orchestrating the body’s natural immune response to the virus.
It seems beta has the edge according to this report.
"For IFN-ß, the virus titers were below the detection limit at all concentrations tested (50 u/ml-1000u/ml), indicating more potent anti-SARS-CoV-2 activity than IFN-a"
https://www.immunology.ox.ac.uk/covid-19/literature-digest-old/sars-cov-2-is-sensitive-to-type-i-interferon-pretreatment
Another study (University of Oxford) - Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection
This report highlights that Interferon beta is more effective that alpha!
Some snippets to enjoy:
Herein, we report the remarkable sensitivity of SARS-CoV-2 to recombinant human interferons a and ß (IFNa/ß).
Herein, we report that type I IFNs exhibited potent anti-SARS-CoV-2 activities in cultured cells, demonstrating the therapeutic potency of type I IFNs for COVID-19.
For IFN-ß, the virus titers were below the detection limit at all concentrations tested (50 u/ml-1000u/ml), indicating more potent anti-SARS-CoV-2 activity than IFN-a. Consistently, no CPE was observable under microscopic examination in all IFN-treated samples.
Taken together, these results indicate that treatment with low concentrations of both IFN-a and IFN-ß significantly inhibited viral infection, with IFN-ß being slightly more effective than IFN-a.
Our data clearly demonstrate that SARS-CoV-2 is highly sensitive to both IFN-a and IFN-ß treatment in cultured cells.
Our data may provide an explanation, at
145 least in part, to the observation that approximately 80% of patients actually develop mild symptoms and recover (7). It is possible that many of them are able to mount IFN-a/ß-mediated innate immune response upon SARS-CoV-2 infection, which helps to limit virus infection/dissemination at an early stage of disease
There's been a real flurry of activity this week with new studies and reports relating to Interferon treatment. The early Chinese study of medical workers was very encouraging, but can't be relied on. I think there will be a lot of people looking towards the Synairgen results as the first un-biased, clinical study.
And another study in Western Australia is starting later this month to test Interferon treatment to help stop Covid-19.
An exploratory study by Professor Kollmann and collaborators in Wuhan, Hubei Province, China (the original epicentre of the current pandemic) found that interferon therapy reduced the duration that a patient was infectious.
“We want to see whether administering interferon to those positive cases and those who have been recently exposed to a case could possibly stop the spread of the virus and, with that, the pandemic.”
This is a potentially interesting side benefit of interferon treatment. It can also help to prevent the virus shedding and reduce transmission. There is a lot of talk in the press about the R-number, and how many people one person can infect. If potentially interferon can reduce the R number then we limit the spread of the virus and the damaging economic effects of lockdown can be relieved....